CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
Hye-yon Cho, Yong-Beom Kim, Wook-ha Park, Jae Hong No
Cancer Research and Treatment. 2021;53(3):819-828.   Published online 2020 December 16    DOI: https://doi.org/10.4143/crt.2020.1013

Excel Download

Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
Cancer Research and Treatment. 2021;53(3):819-828   Crossref logo
Link1 Link2 Link3

Rucaparib: a novel PARP inhibitor for&nbsp;<em>BRCA</em>&nbsp;advanced ovarian cancer
Drug Design, Development and Therapy. 2018;Volume 12:605-617   Crossref logo
Link1 Link2

P-057 Expression of the cyclin-dependent kinase inhibitor p21 is linkedto regulation of RAD51 in response to etoposide treatment of small cell lung cancer cells
Lung Cancer. 2005;49:S129   Crossref logo
Link1 Link2

Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer
. 2022;   Crossref logo
Link1 Link2

Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells
Gynecologic Oncology. 2018;149:69   Crossref logo
Link1 Link2

Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer
BMC Cancer. 2022;22(1):   Crossref logo
Link1 Link2 Link3

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
PLOS ONE. 2018;13(11):e0207399   Crossref logo
Link1

Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer
Journal of Pharmacy Practice. 2017;32(2):219-224   Crossref logo
Link1 Link2 Link3

Checkpoint Kinase 1 Activation Enhances Intestinal Epithelial Barrier Function via Regulation of Claudin-5 Expression
PLOS ONE. 2016;11(1):e0145631   Crossref logo
Link1

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?
Cancer Science. 2012;103(7):1195-1200   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.